# Local Injection and Systemic Therapy in the Treatment of NSCLC.

> **NCT06618391** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 84 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Envafolimab
- **DRUG:** Recombinant human endostatin
- **DRUG:** recombinant human adenovirus type 5

## Key facts

- **NCT ID:** NCT06618391
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2026-03-02
- **Final completion:** 2026-10-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06618391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06618391, "Local Injection and Systemic Therapy in the Treatment of NSCLC.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT06618391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*